* Cellegy Pharmaceuticals Inc., of Foster City, Calif., has licensed itsinvestigational compound, Glyorin, to Glaxo Wellcome Inc., ofResearch Triangle, N.C. Glylorin entered Phase III clinical trials inJanuary, 1996, for nonbullous congenital ichthyosiform erythrodermaand is also expected to be evaluated in the treatment of other lesssevere forms of the disease.

* Depotech Corp., of San Diego, has filed an investigational newdrug application with the FDA to begin Phase 1 clinical trials ofDepoMorphine, a sustained-release DepoFoam formulation ofmorphine used to treat acute post-surgical pain.

(c) 1997 American Health Consultants. All rights reserved.